



FOR IMMEDIATE RELEASE

TSX: BMR

BRADMER APPOINTS PAUL VAN DAMME CHIEF FINANCIAL OFFICER

Toronto, Ontario – September 12, 2007 – Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that the Board of Directors has appointed Paul J. Van Damme, MBA, CA, to the position of Chief Financial Officer effective September 12, 2007. Mr. Brian Brohman will continue to serve in a leadership position as Chief Business Officer of the Company.

“Mr. Van Damme brings significant expertise in corporate finance, corporate governance and compliance, and investor relations to the management team at Bradmer,” said Dr. Alan M. Ezrin, Chief Executive Officer of Bradmer. “With an extensive background in the life science sector for public companies listed in both Canada and the United States, Paul adds tremendous depth to our team and will play a key role in our future growth.”

Mr. Van Damme has previously held the senior finance position on the management team of three publicly traded life science companies, Vasogen Inc., Lorus Therapeutics Inc. and NPS Pharmaceuticals, Inc. (formerly Allelix Biopharmaceuticals Inc.). Mr. Van Damme currently serves on the Board of Directors and the Audit Committee of the Ontario Genomics Institute. Earlier in his career, Mr. Van Damme was an Audit Manager for PricewaterhouseCoopers. He is a member of a number of professional associations including the Association for Investment Management and Research and Financial Executives International. He received his Master in Business Administration from the Rotman School of Management at the University of Toronto.

About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)

Bradmer Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. To date, over US\$60 million in grants and related support has driven research and development of the licensed treatment, which has been delivered to over 200 patients with promising results and has completed Phase II clinical trials at Duke University. Bradmer is currently in the process of organizing a prospective multi-center clinical trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.

Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

For further information contact:

Bradmer Pharmaceuticals Inc.
Mr. Brian Brohman
Chief Business Officer
Phone: (416) 361-6058 (Ext. 804)
E-mail: bbrohman@bradmerpharma.com
Internet: www.bradmerpharma.com

Investor Relations
Ross Marshall
The Equicom Group Inc.
Phone: (416) 815-0700 (Ext. 238)
Fax: (416) 815-0080
E-mail: rmarshall@equicomgroup.com